Barcelona-Catalonia has become one of Europe’s most compelling life sciences ecosystems, combining 1,400+ companies, world-class hospitals and research centers, and a fast-growing base in AI, digital health, and advanced therapies. With operating costs 40-60% lower than traditional hubs and internationally experienced talent, it offers U.S. companies a scalable, competitive platform for life sciences growth in Europe.
Barcelona-Catalonia is Europe’s preferred base for U.S. life sciences leaders, including Amgen, Teladoc Health, Zoetis, and AstraZeneca–Alexion, which is developing one of its largest European R&D hubs in Barcelona. The whitepaper explores the data, cost benchmarks, and case studies behind Barcelona-Catalonia’s rise, and outlines why it is viewed by U.S. executives as a strategic operating advantage in Europe.
Offered Free by: Catalonia Trade & Investment
See All Resources from: Catalonia Trade & Investment
